Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

A New Strategy for Obesity Treatment: Revealing the Frontiers of Anti-obesity Medications

In Press, (this is not the final "Version of Record"). Available online 04 January, 2024
Author(s): Pan-feng Huang, Qi-Yu Wang, Rong-Bin Chen, Ya-Di Wang, Yuan-Yuan Wang, Jiang-Hua Liu, Xin-Hua Xiao* and Zhe-Zhen Liao
Published on: 04 January, 2024

DOI: 10.2174/0115665240270426231123155924

Price: $95

conference banner
Abstract

Obesity dramatically increases the risk of type 2 diabetes, fatty liver, hypertension, cardiovascular disease, and cancer, causing both declines in quality of life and life expectancy, which is a serious worldwide epidemic. At present, more and more patients with obesity are choosing drug therapy. However, given the high failure rate, high cost, and long design and testing process for discovering and developing new anti-obesity drugs, drug repurposing could be an innovative method and opportunity to broaden and improve pharmacological tools in this context. Because different diseases share molecular pathways and targets in the cells, anti-obesity drugs discovered in other fields are a viable option for treating obesity. Recently, some drugs initially developed for other diseases, such as treating diabetes, tumors, depression, alcoholism, erectile dysfunction, and Parkinson's disease, have been found to exert potential anti-obesity effects, which provides another treatment prospect. In this review, we will discuss the potential benefits and barriers associated with these drugs being used as obesity medications by focusing on their mechanisms of action when treating obesity. This could be a viable strategy for treating obesity as a significant advance in human health.

Keywords: obesity, drug repurposing, drug reuse, drug repositioning, pharmacotherapy.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy